Xu Renbiao, Member of the Standing Committee of the Taizhou Municipal Party Committee and Secretary of the Wenling Municipal Party Committee, inspected Wanbangde Pharmaceutical to guide the company in resuming production and operations as well as its COVID-19 prevention and control efforts.

Chairman Zhao Shouming delivered a report on relevant issues. Wanbangde Pharmaceutical has been gradually resuming production since February 10, and as of today, 30% of its total workforce—entirely employees from Wenling—have returned to work. For employees originating from provinces with higher concentrations of such workers, the company plans to arrange chartered buses to bring them back in stages, after which they will be accommodated in hotels and selected employee dormitories for mandatory isolation and observation. He emphasized that, to ensure a smooth resumption of business operations while maintaining strict epidemic prevention measures, the company has implemented a comprehensive防疫 (epidemic prevention) plan and established a leading group dedicated to controlling and responding to the novel coronavirus outbreak. The chairman serves as the group’s leader, with other senior management team members acting as deputy leaders. Additionally, deputy general managers overseeing various business divisions, along with heads of departments, workshop directors, and key personnel, have been appointed as core members, each assigned clear responsibilities to effectively manage the company’s epidemic response and emergency protocols.To safeguard employee health, the company has established comprehensive health records for every staff member, adopting an "individual file" system. Additionally, the company is pursuing a multi-faceted approach to balancing safety with productivity: enhancing protective measures, providing thorough training on COVID-19 prevention and control, intensifying public awareness campaigns about防疫 knowledge, conducting regular temperature checks, implementing contactless boxed meal distribution, enforcing strict isolation monitoring, and strengthening overall supervision. As of now, the company has already stockpiled a substantial supply of medical masks, disinfectants, and other essential protective materials, such as alcohol.

Following this, Secretary Xu Renbiao highly commended Wanbande for actively fulfilling its social responsibilities during the epidemic prevention and control period, demonstrating heartfelt generosity by leveraging its overseas market channels to urgently procure 78,500 N95 masks and over 100 temperature guns, thereby supporting Taizhou City and Wenling City in their fight against the outbreak. He also expressed his hope that Wanbande will continue to dedicate itself to social公益 initiatives in its future development, further showcasing the company’s commitment and sense of responsibility.

Chairman Zhao Shouming delivered a report on relevant issues. Wanbangde Pharmaceutical has been gradually resuming production since February 10, and as of today, 30% of its total workforce—entirely employees from Wenling—have returned to work. For employees originating from provinces with higher concentrations of such workers, the company plans to arrange chartered buses to bring them back in stages, after which they will be accommodated in hotels and selected employee dormitories for mandatory isolation and observation. He emphasized that, to ensure a smooth resumption of business operations while maintaining strict epidemic prevention measures, the company has implemented a comprehensive防疫 (epidemic prevention) plan and established a leading group dedicated to controlling and responding to the novel coronavirus outbreak. The chairman serves as the group’s leader, with other senior management team members acting as deputy leaders. Additionally, deputy general managers overseeing various business divisions, along with heads of departments, workshop directors, and key personnel, have been appointed as core members, each assigned clear responsibilities to effectively manage the company’s epidemic response and emergency protocols. To safeguard employee health, the company has set up detailed health records for every staff member, adopting an "individual file" system. Furthermore, the company is taking a multi-pronged approach to balancing safety and productivity: enhancing protective measures, providing thorough training on COVID-19 prevention and control, intensifying public awareness campaigns about防疫 knowledge, conducting regular temperature checks, implementing contactless boxed meal distribution, enforcing rigorous isolation monitoring, and strengthening overall supervision. As of now, the company has already stockpiled a significant supply of medical masks, disinfectants, and other essential protective materials like alcohol.

Secretary Xu Renbiao emphasized that, in the face of a major epidemic, Wanbangde Pharmaceutical must take the lead as a publicly listed company, rigorously fulfilling its primary responsibility for prevention and control, with the safety and health of employees as its top priority. As production and work resume, it’s crucial to ensure that all preventive measures are fully implemented—this includes thorough personnel screening, robust internal safety management, and adequate supply of protective materials. Additionally, regular disinfection should be carried out across key areas such as production workshops, office buildings, employee cafeterias, and dormitories, while also boosting employees' awareness of personal protection. This way, we can keep safety risks firmly under control throughout the pandemic.

Following this, Secretary Xu Renbiao highly praised Wanbande for actively fulfilling its social responsibilities during the epidemic prevention and control period, demonstrating heartfelt generosity by leveraging its overseas market channels to urgently procure 78,500 N95 masks and over 100 temperature guns, thereby supporting Taizhou City and Wenling City in their fight against the outbreak. He also expressed his hope that Wanbande will continue to dedicate itself to social公益 initiatives in its future development, further showcasing the company’s commitment and sense of responsibility.

Secretary Xu Renbiao also carefully inquired about the research efforts undertaken by Wanbangde Pharmaceutical in tackling the COVID-19 pandemic. Chairman Zhao Shouming explained that on February 13, the Zhejiang Provincial Administration of Food and Drug and the Zhejiang Provincial Health Commission organized expert reviews and approved Wanbangde’s initiative to launch an emergency clinical research project focused on using its bromhexine hydrochloride tablets for the treatment of pneumonia caused by the novel coronavirus infection, along with innovative application studies. Currently, this project has been urgently kicked off, led by the Second Affiliated Hospital of Wenzhou Medical University, with full cooperation from Wanbangde Pharmaceutical. Meanwhile, the company is steadily advancing related drug research activities. Secretary Xu Renbiao emphasized that enterprises must act swiftly and efficiently, dedicating every minute to accelerating clinical research and innovative applications aimed at combating the COVID-19 outbreak—and ultimately contributing to the successful defense against the epidemic.

Finally, Secretary Xu Renbiao addressed the challenges faced by the company in its industrial development, instructing relevant departments on-site to establish a dedicated task force. He emphasized streamlining approval processes and assigning specific personnel to oversee Wanbangde’s projects, ensuring comprehensive support and actively facilitating the resolution of any difficulties or issues the company encounters during its growth.